Viking Therapeutics' stock rose over 27% after trial data showed its obesity drug VK2735 maintained significant weight loss in patients even with less frequent dosing. The drug, targeting appetite regulation receptors GLP-1 and GIP, helped patients keep up to 97% of their initial weight loss on biweekly dosing and 90% on monthly dosing, outperforming placebo. Side effects were similar to placebo, and the company plans to study oral dosing next. This suggests flexible dosing could improve long-term treatment adherence and sustained weight management.
Viking Therapeutics' recent surge in shares on weight loss drug maintenance data is notable. For readers following the health sector, here is Pluang's market snapshot as of Sep 22, 2026 22:01 WIB: Among 101 priced US health stocks tradable on Pluang, 71 rose and 29 fell today. Notable movers include NUWE at USD 0.84 with a 1-day change of -3.87% and Pluang order activity showing 13% Sell / 87% Buy, TXG at USD 82.07 up 3.75% with 96% Sell / 4% Buy, and BAX at USD 23.79 up 3.73% with a typical hold time of 72 days.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
Dogecoin surged up to 15% on September 21, reaching $0.105, its highest price in months. The rally was fueled by large whale accumulations of 240-360 million DOGE tokens, a wave of short position liquidations totaling over $12 million, and record dai...
